RT @VivekSubbiah: In 2012 we published --> Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermi…
RT @VivekSubbiah: In 2012 we published --> Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermi…
RT @VivekSubbiah: In 2012 we published --> Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermi…
In 2012 we published --> Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist @MCT_AACR @OncoAlert @weldeiry @JTrentMDPhD @Dr_R_Kurzrock https://t.co/AGxzQ0Zg
RT @VivekSubbiah: Rationale was from previous publication in @MCT_AACR Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant…
RT @VivekSubbiah: Rationale was from previous publication in @MCT_AACR Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant…
RT @VivekSubbiah: Rationale was from previous publication in @MCT_AACR Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant…
Rationale was from previous publication in @MCT_AACR Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist @JTrentMDPhD @Dr_R_Kurzrock https://t.co/RJHYp6Px8S
RT @JTrentMDPhD: DDR5 inhibitor used in phase 1 study of patients with advanced chondrosarcoma seems promising. @ctosociety #ctos2021 by @V…
RT @JTrentMDPhD: DDR5 inhibitor used in phase 1 study of patients with advanced chondrosarcoma seems promising. @ctosociety #ctos2021 by @V…
RT @JTrentMDPhD: DDR5 inhibitor used in phase 1 study of patients with advanced chondrosarcoma seems promising. @ctosociety #ctos2021 by @V…
RT @JTrentMDPhD: DDR5 inhibitor used in phase 1 study of patients with advanced chondrosarcoma seems promising. @ctosociety #ctos2021 by @V…
DDR5 inhibitor used in phase 1 study of patients with advanced chondrosarcoma seems promising. @ctosociety #ctos2021 by @VivekSubbiah @breelynwilkyMD et al. 11% PR rate. mPFS 7.4 months. Rationale based on our prior study: https://t.co/C7I6BY7F5K https:/
@corrie_painter @1111linno @JAMAOnc @JAMANetwork Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist https://t.co/RJHYp6Px8S
RT @VivekSubbiah: Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic R…
RT @VivekSubbiah: Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic R…
RT @VivekSubbiah: Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic R…
@JTrentMDPhD @weldeiry @SarcomaOncology @Santchawla1 @APConley77 @HuangLabICR @breelynwilkyMD @ctosociety @OncoAlert @bcarneiro7 This expansion cohort was inspired from a previous case of chondrosarcoma responding to DR4/5 inhibition @JTrentMDPhD @Dr_R_Kur
Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist @MCT_AACR @MCT_AACR https://t.co/RJHYp6Px8S